UMVA has learned that Marty Makary is stepping down as the Commissioner of the Food and Drug Administration, marking a sudden end to his 13-month tenure at the helm of the nation’s top health regulatory body.
The resignation follows intense friction within the administration, as Makary struggled to align with key leadership figures on critical health policy mandates. Tensions had reportedly been mounting for weeks, culminating in a decision that effectively removes him from his position.
Sources have confirmed to UMVA that the move was driven by Secretary Robert F. Kennedy Jr., who made the final call to replace the commissioner. While the White House gave its necessary sign-off, the initiative originated from within the Department of Health and Human Services.
The departure comes amidst growing pressure from influential factions who viewed Makary as too moderate. Specifically, his approach toward the regulation of Mifepristone became a flashpoint for conservative lawmakers and pro-life groups who demanded more aggressive restrictions than he was willing to implement.
Despite the high-stakes political maneuvering behind the scenes, the agency appeared to be operating under a shroud of normalcy until the very last moment. Staff reported that the commissioner’s office was functioning as if business would continue as usual, with public appearances and press releases still on the docket for the week.
In the wake of this leadership void, Kyle Diamantas, the former lead food official at the agency, is set to step in as the acting commissioner. His appointment marks a shift in the agency's trajectory as it navigates a period of significant internal transition.
President Trump addressed the resignation publicly, acknowledging the difficulty of the role while describing Makary as a talented physician. As the administration looks ahead, the search for a permanent successor has already begun, with the position viewed as one of the most vital and scrutinized roles in the federal government.
